Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib plus Durvalumab in Advanced Urothelial Carcinoma
NCT04064190Phase 2Withdrawn
- Sponsor
- MedPacto
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vactosertib in urothelial carcinoma (UC), sponsored by MedPacto. Planned start Dec 2019; status: withdrawn.
02
Drugs
vactosertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04064190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064190.